Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine GSK 1557484A.
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 12 Apr 2009 Status changed from not yet recruiting to completed Last checked against ClinicalTrials.gov record.
- 25 Mar 2009 Actual end date March 2009 added as reported by ClinicalTrials.gov.
- 17 Sep 2008 New trial record.